Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 pos POLE mut |
Therapy | Pembrolizumab |
Indication/Tumor Type | colorectal cancer |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 pos POLE mut | colorectal cancer | no benefit | Pembrolizumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, treatment with Keytruda (pembrolizumab) (n=7) or an anti-PD-1/anti-CTLA4 combination therapy (n=1) resulted in responses in 50% (4/8; 1 complete response, 3 partial responses) of metastatic colorectal cancer patients with high microinstability or POLE mutations, and PD-L1 (CD274) expression was not associated with response (PMID: 29998005). | 29998005 |
PubMed Id | Reference Title | Details |
---|---|---|
(29998005) | Immune profiling of microsatellite instability-high and polymerase ε (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. | Full reference... |